Evaluating how quickly Chlamydia and Gonorrhea clear after treatment
Time to Clearance of Chlamydia Trachomatis and Neisseria Gonorrhoeae RNA After Treatment: a Prospective Cohort Study
NA · University Hospital, Strasbourg, France · NCT06216964
This study is testing how quickly Chlamydia and Gonorrhea go away after treatment in people who have these infections.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 140 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Strasbourg, France (other) |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06216964 on ClinicalTrials.gov |
What this trial studies
This study aims to assess the time it takes for Chlamydia trachomatis and Neisseria gonorrhoeae RNA to become undetectable following treatment for uncomplicated infections. Participants will include individuals who have received standard therapies for these infections and will be monitored for the negativation of PCR results. The study focuses on urogenital, oropharyngeal, and anal infections, providing valuable data on treatment efficacy. By tracking the clearance times, the study seeks to improve understanding of treatment outcomes for these common sexually transmitted infections.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 who have had uncomplicated Chlamydia or Gonorrhea infections treated with recommended therapies.
Not a fit: Patients with complicated infections or severe immunosuppression may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment protocols and better management of Chlamydia and Gonorrhea infections.
How similar studies have performed: Other studies have shown varying success in evaluating treatment outcomes for Chlamydia and Gonorrhea, but this specific approach to measuring negativation time is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * \- Patients attending the Trait d'Union department at the Nouvel Hôpital Civil for PrEP consultations, AES or HIV infection. * Over 18 years of age * Male or female * Who have had an uncomplicated CT and/or NG infection treated with currently recommended therapies (Ceftriaxone 500mg DU for NG infections, Doxycycline 200mg per day for 1 week for rectal CT infections and Azithromycin 1g DU or Doxycycline 7 days for other CT infections). * Subject affiliated to a social health insurance scheme * Subject able to understand the aims and risks of the research and to give dated and signed informed consent Exclusion Criteria: * \- Complicated CT and/or NG infections: epididymitis, prostatitis, upper genital infection, extra-genital involvement (keratoconjunctivitis, arthritis, skin involvement, Fiessinger-Leroy-reiter syndrome, Fitz-Hugh-Curtis syndrome). * Interfering treatments and associated diseases: Severe immunosuppression (HIV infection with CD4 less than 200/mm3, chemotherapy in the last 6 months, active haemopathy, congenital immune deficiency, immunosuppressive treatment including corticosteroid therapy for more than 4 weeks or organ transplant. * Impossibility of giving the subject informed information (subject in an emergency situation, difficulties in understanding the subject, etc.). * Subject under court protection * Subject under guardianship or curatorship
Where this trial is running
Strasbourg
- Service du Trait d'Union — Strasbourg, France (RECRUITING)
Study contacts
- Study coordinator: Axel Ursenbach, MD
- Email: axel.ursenbach@chru-strasbourg.fr
- Phone: 0033.88.15.13.52
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Chlamydia Trachomatis, Neisseria Gonorrhoeae, Uncomplicated Infections